Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Musculoskelet Neuronal Interact. 2004 Sep;4(3):293-300.

Bone cancer pain and the role of RANKL/OPG.

Author information

  • 1Dept of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN 55455, USA. clohi001@umn.edu

Abstract

Cancer-induced bone diseases are common and can have a devastating impact at the end of life. One of the most difficult sequelae of cancer is metastases to the skeleton, an event that results in bone destruction and bone cancer pain. Bone cancer pain is usually progressive as the disease advances, and is particularly difficult to treat. Recently, experimental models of bone cancer pain have been developed and have provided seminal insight in understanding the pathophysiology of bone cancer pain. Animal models of bone cancer provided the finding that bone destruction (osteolysis) is associated with pain, and it has been determined that cancer-induced osteolysis is mediated by osteoclasts. Having established that RANK ligand contributed to cancer-induced osteoclastogenesis, it was determined that disruption of the RANKL-RANK axis with OPG inhibited tumor-induced osteoclastogenesis and decreased bone cancer pain.

PMID:
15615497
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for International Society of Musculoskeletal and Neuronal Interactions
    Loading ...
    Write to the Help Desk